Repeated Lu-177-PSMA-617 radioligand therapy using treatment activities up to 9.3 GBq

Current treatment protocols for (177)Lu-PSMA-617 therapies were cautiously derived from dosimetry data, but their practical appropriateness have not yet been proven clinically. We retrospectively report our clinical observations using four different treatment activities. Methods: Forty patients with advanced prostate cancer and positive uptake in PSMA-imaging were treated in fractions of 4 GBq / 80 nmol, 6 GBq / 120 nmol, 7.4 GBq / 150 nmol or 9.3 GBq / 150 nmol (177)Lu-activity / precursor-amount (n = 10, respectively) every 2 months. Safety lab was checked every 2 weeks, PSA-response every 4 weeks; other effects were assessed per anamnesis. Results: Initial PSA response presented no correlation to treatment activity. However, 2/10, 4/10, 4/10 and 7/10 patients with doses of 4, 6, 7.4 and 9.3 GBq were in partial remission 8 weeks after completing all 3 cycles; This would be in line with, but due to low patient numbers not proving, a positive dose-response-relationship. Acute hematological toxicity was also irrespective of treatment activity and no more than one grade-3/4 toxicity was observed in each group. Nevertheless, in contrast to the other groups the mean platelet count in the 9.3 GBq group chronically decreased over time. Conclusion: If patients with diffuse red marrow infiltration and extensive chemotherapeutical pretreatments are excluded, treatment activities up to three injections of 9.3 GBq (177)Lu-PSMA-617 every two months are well tolerable. Further dose escalation should be conducted with care as the MTD seems to be close.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017 Aug 10 [Epub ahead of print]

Hendrik Rathke, Frederik L Giesel, Paul Flechsig, Klaus Kopka, Walter Mier, Markus Hohenfellner, Uwe Haberkorn, Clemens Kratochwil

University Hospital Heidelberg, Germany., German Cancer Research Center (dkfz), Germany.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe